Cancer Cell International

SJR Rank #1,847H-index: 100SJR: 1.750Best quartile: Q1Open AccessAPC: US$3,190Listed in DOAJ
Journal website: aims, scope and author guidelines
Publisher

BioMed Central Ltd

Country

United Kingdom

Type

journal

SJR by Edition

2022202500.450.91.351.8

Subject Categories

  • GeneticsQ1
  • OncologyQ1
  • Cancer ResearchQ2

Areas: Biochemistry, Genetics and Molecular Biology · Medicine

Most published research topics

Cancer-related molecular mechanisms researchMicroRNA in disease regulationFerroptosis and cancer prognosisCircular RNAs in diseasesCancer Cells and MetastasisCancer Immunotherapy and BiomarkersRNA modifications and cancerCancer, Hypoxia, and MetabolismImmune cells in cancerEpigenetics and DNA Methylation

Source: OpenAlex

Publication Statistics

2025 Docs3-Year DocsCitable Docs03006009001200

Documents per Year

202220250150300450600

Detailed Information

ISSN

1475-2867

SJR Best Quartile

Q1

Region

Western Europe

Citations per Document (2 years)

6.89

References per Document

76.81

Coverage

2001-2026

Scope

Cancer Cell International publishes articles on all aspects of cancer cell biology, originating largely from, but not limited to, work using cell culture techniques. The journal focuses on novel cancer studies reporting data from biological experiments performed on cells grown in vitro, in two- or three-dimensional systems, and/or in vivo (animal experiments). These types of experiments have provided crucial data in many fields, from cell proliferation and transformation, to epithelial-mesenchymal interaction, to apoptosis, and host immune response to tumors. Cancer Cell International also considers articles that focus on novel technologies or novel pathways in molecular analysis and on epidemiological studies that may affect patient care, as well as articles reporting translational cancer research studies where in vitro discoveries are bridged to the clinic. As such, the journal is interested in laboratory and animal studies reporting on novel biomarkers of tumor progression and response to therapy and on their applicability to human cancers.

Metrics from SCImago Journal Rank 2025. View on SCImago